A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The development of non-genotoxic therapies that activate wild-type p53 in tumors is of great interest since the discovery of p53 as a tumor suppressor. Here we report the identification of over 100 small-molecules activating p53 in cells. We elucidate the mechanism of action of a chiral tetrahydroindazole (HZ00), and through target deconvolution, we deduce that its active enantiomer (R)-HZ00, inhibits dihydroorotate dehydrogenase (DHODH). The chiral specificity of HZ05, a more potent analog, is revealed by the crystal structure of the (R)-HZ05/DHODH complex. Twelve other DHODH inhibitor chemotypes are detailed among the p53 activators, which identifies DHODH as a frequent target for structurally diverse compounds. We observe that HZ compounds accumulate cancer cells in S-phase, increase p53 synthesis, and synergize with an inhibitor of p53 degradation to reduce tumor growth in vivo. We, therefore, propose a strategy to promote cancer cell killing by p53 instead of its reversible cell cycle arresting effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 2×
“The co-crystal structure also provides an explanation for the poor inhibitory properties of the inactive analog HZ25 ( 4 ) (Fig.”
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites
Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., & Siuzdak, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812874106 · Cited by 2,677
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Physiological concentrations of purines and pyrimidines
Traut, T. W. (1994) · Molecular and Cellular Biochemistry · doi:10.1007/bf00928361 · Cited by 1,867
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Self-citationCorbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Sykes, D. B., Kfoury, Y. S., Mercier, F. E., Wawer, M. J., Law, J. M., Haynes, M. K., Lewis, T. A., Schajnovitz, A., Jain, E., Lee, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.057 · Cited by 500
On Dihydroorotate Dehydrogenases and Their Inhibitors and Uses
Munier-Lehmann, H., Vidalain, P.-O., Tangy, F., & Janin, Y. L. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301848w · Cited by 209 · cited 3×
“Several additional DHODH inhibitors with unrelated structures have been reported in the literature 10,17 – 22 .”
Brown, K. K., Spinelli, J. B., Asara, J. M., & Toker, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0611 · Cited by 198
Cited by
Mitochondrial Metabolism as a Target for Cancer Therapy
Vasan, K., Werner, M., & Chandel, N. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.019 · Cited by 736
Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer
Boukalova, S., Hubackova, S., Milosevic, M., Ezrova, Z., Neuzil, J., & Rohlena, J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165759 · Cited by 161
Hubackova, S., Davidova, E., Boukalova, S., Kovarova, J., Bajzikova, M., Coelho, A., Terp, M. G., Ditzel, H. J., Rohlena, J., & Neuzil, J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2224-7 · Cited by 58
“For immunoblotting, the following antibodies were used: anti-RPS6 (#2217), anti-p53 pS15 (#9282), anti-H3 pS10 (#3642), anti-Chk1 pS317 (#2344), anti-Chk2 pT68 (#2661) (all from Cell Signaling Technology, Danvers, MA, USA), anti-Chk2 (sc-9064), anti-Chk1 (sc-8408), anti-RPA32 (sc-56770), anti-Ub (sc-8017), anti-p53 (s…”
InfluentialComplementing machine learning‐based structure predictions with native mass spectrometry
Allison, T. M., Degiacomi, M. T., Marklund, E. G., Jovine, L., Elofsson, A., Benesch, J. L. P., & Landreh, M. (2022) · Protein Science · doi:10.1002/pro.4333 · Cited by 20
Miyake, S., & Masuda, S. (2022) · RNA Biology · doi:10.1080/15476286.2022.2146919 · Cited by 4
“It has also been reported to be activated by brequinar to evoke downstream immune factor responses [20], and p53, a typical downstream factor of ATM, is activated by DHODH inhibitors [32,41].”
Background
Metadata
- Authors
- Ladds, M. J. G. W., van Leeuwen, I. M. M., Drummond, C. J., Chu, S., Healy, A. R., Popova, G., Pastor Fernández, A., Mollick, T., Darekar, S., Sedimbi, S. K., Nekulova, M., Sachweh, M. C. C., Campbell, J., Higgins, M., Tuck, C., Popa, M., Safont, M. M., Gelebart, P., Fandalyuk, Z., Thompson, A. M., Svensson, R., Gustavsson, A.-L., Johansson, L., Färnegårdh, K., Yngve, U., Saleh, A., Haraldsson, M., D’Hollander, A. C. A., Franco, M., Zhao, Y., Håkansson, M., Walse, B., Larsson, K., Peat, E. M., Pelechano, V., Lunec, J., Vojtesek, B., Carmena, M., Earnshaw, W. C., McCarthy, A. R., Westwood, N. J., Arsenian-Henriksson, M., Lane, D. P., Bhatia, R., McCormack, E., & Laín, S.
- Venue
- Nature Communications
- Published
- 2018-03-16
- Volume
- 9
- Issue
- 1
- Pages
- 1107-1107
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2793033519
- Cited by
- 89
- References
- 12
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. https://app.cochat.ai/papers/10.1038/s41467-018-03441-3
- The paper
- Ladds, M. J. G. W., van Leeuwen, I. M. M., Drummond, C. J., Chu, S., Healy, A. R., Popova, G., Pastor Fernández, A., Mollick, T., Darekar, S., Sedimbi, S. K., Nekulova, M., Sachweh, M. C. C., Campbell, J., Higgins, M., Tuck, C., Popa, M., Safont, M. M., Gelebart, P., Fandalyuk, Z., . . . Laín, S. (2018). A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nature Communications. https://doi.org/10.1038/s41467-018-03441-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.